Multiple endocrine neoplasia (MEN 1 and MEN 2)
- Synonyms
- MEN, MEN1, MEN2, Wermer syndrome, Sipple syndrome, multiple endocrine neoplasia type 2
- Specialty
- Internal medicine · Endocrinology & diabetes
- Images
- Histology 1 · Ultrasound 1
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Images (2)
Histology
UltrasoundDefinition
Multiple endocrine neoplasias (MEN) are autosomal dominant inherited syndromes in which hyperplasia or tumors develop in several endocrine glands, simultaneously or sequentially.
- MEN 1: parathyroids, endocrine pancreas or duodenum and pituitary; caused by inactivating mutations of the MEN1 gene, which encodes the tumor suppressor protein menin.
- MEN 2A: medullary thyroid carcinoma, phaeochromocytoma and primary hyperparathyroidism; familial medullary thyroid carcinoma is considered a distinct variant.
- MEN 2B: medullary thyroid carcinoma, phaeochromocytoma, mucosal neuromas, intestinal ganglioneuromatosis and a marfanoid habitus – without hyperparathyroidism.
MEN 2A, MEN 2B and familial medullary carcinoma are caused by activating mutations of the RET proto-oncogene on chromosome 10, which encodes a receptor tyrosine kinase.
Classification
MEN 1 – manifestations
- Primary hyperparathyroidism: in 95 % or more; diffuse, often asymmetric hyperplasia of several glands is typical.
- Pancreatic or duodenal neuroendocrine tumors: in 30–90 %; often multicentric. The most common functioning tumor is gastrinoma, followed by insulinoma; about one third of patients have non-functioning tumors. About 30 % are already metastatic at diagnosis.
- Pituitary tumors: in 15–42 %; of these 25–90 % are prolactinomas, about 25 % secrete GH or GH and prolactin, about 3 % secrete ACTH, and most of the rest are non-functioning.
- Other manifestations: foregut carcinoids (thymus, lung, stomach) in 5–15 %, thymic carcinoids more often in men; adrenal adenomas in up to 33 %; lipomas, angiofibromas, collagenomas, meningiomas and ependymomas; increased risk of breast cancer.
MEN 2A and MEN 2B – manifestations
- MEN 2A: medullary thyroid carcinoma in almost all patients; phaeochromocytoma in 40–50 % of affected family members, bilateral and multicentric in more than half; hyperparathyroidism in 10–20 %, often involving several glands; cutaneous lichen amyloidosis in some families; Hirschsprung disease in 2–5 %.
- MEN 2B: about 95 % carry the same point mutation in the RET protein (amino acid 918), more than half as new mutations. About 50 % have the complete syndrome of mucosal neuromas, phaeochromocytoma and medullary carcinoma; the medullary carcinoma is particularly aggressive and almost always present by the first year of life.
Occurrence & epidemiology
MEN 1: onset between 4 and 81 years, peak incidence in the third to fifth decades; both sexes equally affected. More than 50 % of mutation carriers develop the disease by age 40 and more than 95 % by age 80. About 40 % have tumors in all three main organs. MEN 2: Of all medullary thyroid carcinomas about 25 % are familial; up to about 7 % of apparently sporadic cases carry a RET mutation.
Clinical features
MEN 1
- Hyperparathyroidism: usually asymptomatic hypercalcemia; about 25 % have kidney stones or nephrocalcinosis.
- Gastrinoma: up to 80 % of patients with MEN 1 have multiple peptic ulcers due to acid hypersecretion or asymptomatically raised gastrin.
- Insulinoma: fasting hypoglycemia, often before the age of 40; tumors are small and often multiple.
- Other pancreatic tumors: watery diarrhea with hypokalemia and achlorhydria (WDHA syndrome); less often ectopic ACTH or CRH (Cushing's syndrome) or GHRH (acromegaly).
- Pituitary tumors: galactorrhoea, acromegaly, Cushing's disease; mass effects with visual disturbance, headache and hypopituitarism.
MEN 2A and MEN 2B
- Medullary thyroid carcinoma: usually develops in childhood from C-cell hyperplasia and is often multicentric.
- Phaeochromocytoma: in MEN 2 produces disproportionately more adrenaline; hypertension is more often paroxysmal than sustained, and hypertensive crises are typical; many patients, however, are asymptomatic.
- Hyperparathyroidism (MEN 2A only): hypercalcemia, kidney stones, nephrocalcinosis.
- Cutaneous lichen amyloidosis (MEN 2A): pruritic, scaly papules between the shoulder blades or on extensor surfaces.
- MEN 2B: glistening bumps (neuromas) on the lips, tongue and buccal mucosa, often the earliest sign; neuromas of the eyelids, conjunctivae and corneas, thickened eyelids, everted lips; altered bowel motility with constipation, diarrhea and occasionally megacolon; marfanoid habitus and skeletal deformities.
Diagnosis
- Suspected MEN 1: with tumors of the parathyroids, pancreas or pituitary, especially with a family history; with primary hyperparathyroidism before the age of 30.
- Laboratory tests in MEN 1: calcium, intact PTH, gastrin and prolactin. Gastrinoma: raised basal gastrin with a paradoxical rise in the secretin test; insulinoma: fasting hypoglycemia with a raised insulin level; acromegaly: raised IGF-1 and absent GH suppression in the glucose tolerance test.
- Imaging in MEN 1: ultrasound, endoscopic ultrasound, CT and MRI; gallium-68 DOTATATE PET/CT was about three times more sensitive than older scintigraphic and CT methods for pancreatic and duodenal tumors and helps to detect thymic and lung carcinoids.
- Laboratory tests in MEN 2: serum calcitonin (medullary carcinoma), calcium, 24-hour urinary calcium and PTH, plasma free metanephrines or urinary catecholamines and metanephrines.
- Imaging in MEN 2: neck ultrasound, complemented by CT, MRI or scintigraphy; CT or MRI to localise phaeochromocytomas and detect bilateral tumors.
- Genetics: panel testing when MEN 1 is suspected (including genes for MEN 4 and other forms of familial hyperparathyroidism); RET testing in all patients with medullary thyroid carcinoma. The specific RET mutation predicts aggressiveness and associated manifestations. First-degree relatives are offered genetic testing.
Treatment principles
- In MEN 1, individual tumours are treated organ by organ, for example primary hyperparathyroidism by extensive parathyroidectomy, and pancreatic neuroendocrine tumours and pituitary adenomas according to type and size.
- In MEN 2, prophylactic thyroidectomy is performed at a time determined by the risk associated with the RET mutation; phaeochromocytoma is excluded or removed first before any other surgery.
- Genetic counselling, testing of relatives and lifelong surveillance are essential.
Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.
Keep learning in the app
Further reading (open access)
Cross-references
More topics: Endocrinology & diabetes
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.
Related pages: Type 2 diabetes mellitus · Primary aldosteronism (Conn's syndrome) · Hyperthyroidism
Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.